Patents by Inventor Richard Eric Olson

Richard Eric Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazo-triazines as corticotropin releasing factor antagonists
    Publication number: 20040023965
    Abstract: The present invention describes novel imidazo-triazines of formula I: 1
    Type: Application
    Filed: April 29, 2003
    Publication date: February 5, 2004
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Patent number: 6579876
    Abstract: The present invention describes novel compounds of formula (Ib): wherein D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as corticotropin releasing factor antagonists.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: June 17, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Publication number: 20030055059
    Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: 1
    Type: Application
    Filed: February 11, 2002
    Publication date: March 20, 2003
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Imidazo-pyridines as corticotropin releasing factor antagonists
    Patent number: 6521636
    Abstract: The present invention describes novel imidazo-pyridines of formula I: wherein D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as corticotropin releasing factor antagonists.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
    Patent number: 6509338
    Abstract: The present invention describes novel pyrazolo[1,5-a]triazines of formula: wherein R3 is an alkyl, alkenyl, alkynyl, or cycloalkyl group, or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: January 21, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard Eric Olson, William Eric Frietze
  • Hydroxyalkanoylaminolactams and related structures as inhibitors of a &bgr; protein production
    Patent number: 6503902
    Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: January 7, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard Eric Olson, Hong Liu, Lorin Andrew Thompson, III
  • Arylamino fused pyridines
    Patent number: 6448261
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I; and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: September 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Patent number: 6365589
    Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 2, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • 6-aryloxy and arylthiopurines
    Patent number: 6258809
    Abstract: Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by this invention are those of the following formulae: wherein R1, R13, X, Y, Z, G and Q are as defined herein.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: July 10, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Parthasarathi Rajagopalan, Robert John Chorvat, Rajagopal Bakthavatchalam, James Peter Beck, Paul Joseph Gilligan, Richard Eric Olson
  • Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives
    Patent number: 6124300
    Abstract: Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by this invention are those of the following formulae: ##STR1## wherein R.sup.1, R.sup.13, X, Y, Z, G and Q are as defined herein.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: September 26, 2000
    Assignee: DuPont Pharmaceuticals
    Inventors: Parthasarathi Rajagopalan, Robert John Chorvat, Rajagopal Bakthavatchalam, James Peter Beck, Paul Joseph Gilligan, Richard Eric Olson
  • Isoxazoline and isoxazole fibrogen receptor antagonists
    Patent number: 6114328
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 5, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Arylamino fused pyrimidines
    Patent number: 6107300
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: August 22, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Isoxazoline and isoxazole fibrinogen receptor antagonists
    Patent number: 5849736
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: December 15, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Isoxazoline fibrinogen receptor antagonists
    Patent number: 5811441
    Abstract: This invention relates to improved isoxazoline compounds including, but not limited to N.sup.2 -(3,5-dimethylisoxazole-4-sulfonyl)-N.sup.3 -?3-(4-amidinophenyl)isoxazolin-5(R)-ylacetyl!-(S)-2,3-diaminopropionic acid, which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: September 22, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Richard Eric Olson, John Wityak
  • Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
    Patent number: 5739163
    Abstract: This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: April 14, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Gary Avonn Cain, Charles Joseph Eyermann, Richard Eric Olson